Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation

Clin Lung Cancer. 2021 Mar;22(2):e157-e159. doi: 10.1016/j.cllc.2020.10.003. Epub 2020 Oct 15.

Authors

Gengpeng Lin¹, Yangli Liu¹, Hui Li², Shuyin Chen³, Yubiao Guo⁴

Affiliations

¹ Department of Pulmonary and Critical Care Medicine, Institute of Pulmonary Diseases, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China.
² Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China.
³ Burning Rock Biotech, Guangzhou, China.
⁴ Department of Pulmonary and Critical Care Medicine, Institute of Pulmonary Diseases, The First Affiliated Hospital of Sun Yat-sen University, Sun Yat-sen University, Guangzhou, China. Electronic address: guoyubiao@outlook.com.

PMID: 33158763
DOI: 10.1016/j.cllc.2020.10.003

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Acrylamides / adverse effects*
Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / genetics
Adenocarcinoma of Lung / pathology
Aged
Aniline Compounds / adverse effects*
Antineoplastic Agents / adverse effects
Carcinoma, Neuroendocrine / drug therapy*
Carcinoma, Neuroendocrine / genetics
Carcinoma, Neuroendocrine / pathology
Drug Resistance, Neoplasm / drug effects
Drug Resistance, Neoplasm / genetics
ErbB Receptors / antagonists & inhibitors
ErbB Receptors / genetics
Female
Gene Fusion
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Protein Kinase Inhibitors / adverse effects
Receptor, Notch2 / genetics*
Receptor, trkA / genetics*

Substances

Acrylamides
Aniline Compounds
Antineoplastic Agents
NOTCH2 protein, human
NTRK1 protein, human
Protein Kinase Inhibitors
Receptor, Notch2
osimertinib
EGFR protein, human
ErbB Receptors
Receptor, trkA